organization · Reporting owner
BCLS II Equity Opportunities, LP
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Solid Biosciences Inc.
Report date February 19, 2025 · Filed February 21, 2025
Jointly reported with Bain Capital Life Sciences Investors, LLC, BCLS SB Investco, LP, Bain Capital Life Sciences Partners, LP, Bain Capital Life Sciences Fund II, L.P., Bain Capital Life Sciences Investors II, LLC, BCLS II Investco, LP, BCLS II Investco (GP), LLC, BCIP Life Sciences Associates, LP, BCLS II Equity Opportunities GP, LLC
Section 16 reporting ended · disclosed 2025-02-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 5,034,582 |
Reported balance
After 2025-02-19 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-02-19 · Purchase · Acquired 1,000,000 · Balance 5,034,582 F1: On February 19, 2025, BCLS II Investco, LP ("BCLS II Investco") purchased 1,000,000 shares of the Issuer's common stock and a pre-funded warrant to purchase 6,444,170 shares of the Issuer's common stock at a purchase price of $4.03 and $4.029, respectively, in an underwritten public offering (the "February 2025 Underwritten Offering"). F4: Represents 528,660 shares of the Issuer's common stock held directly by BCLS SB Investco, LP ("BCLS SB"), 267,257 shares of the Issuer's common stock held directly by Bain Capital Life Sciences Fund II, L.P. ("BCLS Fund II"), 3,301,955 shares of the Issuer's common stock held directly by BCLS II Investco, 904,160 shares of the Issuer's common stock held directly by BCLS II Equity Opportunities, LP ("BCLS II Equity") and 32,550 shares of the Issuer's common stock held directly by BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS II Investco, BCLS SB, BCLS Fund II and BCLS II Equity, the "Bain Capital Life Sciences Entities"), after giving effect to the closing of the February 2025 Underwritten Offering. F6: Bain Capital Life Sciences Partners, LP ("BCLSP") is the general partner of BCLS SB. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS SB. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. F7: Bain Capital Life Sciences Investors II, LLC ("BCLSI II") is the general partner of BCLS Fund II. As a result, BCLSI II may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund II. BCLSI II disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. F8: BCLS II Investco (GP), LLC ("BCLS II Investco GP"), whose managing member is BCLS Fund II, is the general partner of BCLS II Investco. As a result, each of BCLSI II, BCLS Fund II and BCLS II Investco GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS II Investco. Each of BCLSI II, BCLS Fund II and BCLS II Investco GP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. F9: BCLS II Equity Opportunities GP, LLC ("BCLS II Equity GP"), whose manager is BCLS Fund II, is the general partner of BCLS II Equity. As a result, each of BCLSI II, BCLS Fund II and BCLS II Equity GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS II Equity. Each of BCLSI II, BCLS Fund II and BCLS II Equity GP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. F10: Boylston Coinvestors, LLC is the general partner of BCIPLS. F11: Bain Capital Life Sciences Investors, LLC ("BCLSI") (i) is the general partner of BCLSP, (ii) is the manager of BCLSI II and (iii) governs the investment strategy and decision-making process with respect to investments held by BCIPLS. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. |
| Pre-Funded Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee footnotes | 6,444,170 |
Reported balance
After 2025-02-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-02-19 · Purchase · Acquired 6,444,170 · Balance 6,444,170 F1: On February 19, 2025, BCLS II Investco, LP ("BCLS II Investco") purchased 1,000,000 shares of the Issuer's common stock and a pre-funded warrant to purchase 6,444,170 shares of the Issuer's common stock at a purchase price of $4.03 and $4.029, respectively, in an underwritten public offering (the "February 2025 Underwritten Offering"). F2: The pre-funded warrant cannot be exercised if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated with the holder for purposes of Section 13(d) of the Act, would beneficially own more than 9.99% of the total number of shares of the Issuer's common stock then outstanding immediately following such exercise. F3: The pre-funded warrant does not expire. F5: Represents a pre-funded warrant to purchase 6,444,170 shares of the Issuer's common stock held directly by BCLS II Investco, after giving effect to the closing of the February 2025 Underwritten Offering. F8: BCLS II Investco (GP), LLC ("BCLS II Investco GP"), whose managing member is BCLS Fund II, is the general partner of BCLS II Investco. As a result, each of BCLSI II, BCLS Fund II and BCLS II Investco GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS II Investco. Each of BCLSI II, BCLS Fund II and BCLS II Investco GP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. F11: Bain Capital Life Sciences Investors, LLC ("BCLSI") (i) is the general partner of BCLSP, (ii) is the manager of BCLSI II and (iii) governs the investment strategy and decision-making process with respect to investments held by BCIPLS. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 19, 2025, BCLS II Investco, LP ("BCLS II Investco") purchased 1,000,000 shares of the Issuer's common stock and a pre-funded warrant to purchase 6,444,170 shares of the Issuer's common stock at a purchase price of $4.03 and $4.029, respectively, in an underwritten public offering (the "February 2025 Underwritten Offering").
F2: The pre-funded warrant cannot be exercised if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated with the holder for purposes of Section 13(d) of the Act, would beneficially own more than 9.99% of the total number of shares of the Issuer's common stock then outstanding immediately following such exercise.
F3: The pre-funded warrant does not expire.
F4: Represents 528,660 shares of the Issuer's common stock held directly by BCLS SB Investco, LP ("BCLS SB"), 267,257 shares of the Issuer's common stock held directly by Bain Capital Life Sciences Fund II, L.P. ("BCLS Fund II"), 3,301,955 shares of the Issuer's common stock held directly by BCLS II Investco, 904,160 shares of the Issuer's common stock held directly by BCLS II Equity Opportunities, LP ("BCLS II Equity") and 32,550 shares of the Issuer's common stock held directly by BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS II Investco, BCLS SB, BCLS Fund II and BCLS II Equity, the "Bain Capital Life Sciences Entities"), after giving effect to the closing of the February 2025 Underwritten Offering.
F5: Represents a pre-funded warrant to purchase 6,444,170 shares of the Issuer's common stock held directly by BCLS II Investco, after giving effect to the closing of the February 2025 Underwritten Offering.
F6: Bain Capital Life Sciences Partners, LP ("BCLSP") is the general partner of BCLS SB. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS SB. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
F7: Bain Capital Life Sciences Investors II, LLC ("BCLSI II") is the general partner of BCLS Fund II. As a result, BCLSI II may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund II. BCLSI II disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
F8: BCLS II Investco (GP), LLC ("BCLS II Investco GP"), whose managing member is BCLS Fund II, is the general partner of BCLS II Investco. As a result, each of BCLSI II, BCLS Fund II and BCLS II Investco GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS II Investco. Each of BCLSI II, BCLS Fund II and BCLS II Investco GP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
F9: BCLS II Equity Opportunities GP, LLC ("BCLS II Equity GP"), whose manager is BCLS Fund II, is the general partner of BCLS II Equity. As a result, each of BCLSI II, BCLS Fund II and BCLS II Equity GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS II Equity. Each of BCLSI II, BCLS Fund II and BCLS II Equity GP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
F10: Boylston Coinvestors, LLC is the general partner of BCIPLS.
F11: Bain Capital Life Sciences Investors, LLC ("BCLSI") (i) is the general partner of BCLSP, (ii) is the manager of BCLSI II and (iii) governs the investment strategy and decision-making process with respect to investments held by BCIPLS. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 19, 2025 Filed Feb 21, 2025 22:48 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | PurchasePre-Funded Warrant (right to buy) · Derivative | 6,444,170 | $4.03 Strike: $0.00 | $25,963,560.93 |
DisclosureSEC source: 0000950170-25-025011 · ownership.xml · derivative · entry 2 Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner BCLS SB Investco, LP · CIK 0001728056 · 10% owner Bain Capital Life Sciences Partners, LP · CIK 0001703030 · 10% owner Bain Capital Life Sciences Fund II, L.P. · CIK 0001773187 · 10% owner Bain Capital Life Sciences Investors II, LLC · CIK 0001796155 · 10% owner BCLS II Investco, LP · CIK 0001818893 · 10% owner BCLS II Investco (GP), LLC · CIK 0001819101 · 10% owner BCIP Life Sciences Associates, LP · CIK 0001702921 · 10% owner BCLS II Equity Opportunities, LP · CIK 0001814474 · 10% owner BCLS II Equity Opportunities GP, LLC · CIK 0002008174 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 6,444,170 Underlying: Common Stock · 6,444,170 shares Expires not disclosed F1 · kind: On February 19, 2025, BCLS II Investco, LP ("BCLS II Investco") purchased 1,000,000 shares of the Issuer's common stock and a pre-funded warrant to purchase 6,444,170 shares of the Issuer's common stock at a purchase price of $4.03 and $4.029, respectively, in an underwritten public offering (the "February 2025 Underwritten Offering"). F2 · derivative.exercise_date: The pre-funded warrant cannot be exercised if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated with the holder for purposes of Section 13(d) of the Act, would beneficially own more than 9.99% of the total number of shares of the Issuer's common stock then outstanding immediately following such exercise. F3 · derivative.expiration_date: The pre-funded warrant does not expire. F2 · derivative.underlying_shares: The pre-funded warrant cannot be exercised if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated with the holder for purposes of Section 13(d) of the Act, would beneficially own more than 9.99% of the total number of shares of the Issuer's common stock then outstanding immediately following such exercise. F5 · ownership.nature: Represents a pre-funded warrant to purchase 6,444,170 shares of the Issuer's common stock held directly by BCLS II Investco, after giving effect to the closing of the February 2025 Underwritten Offering. F8 · ownership.nature: BCLS II Investco (GP), LLC ("BCLS II Investco GP"), whose managing member is BCLS Fund II, is the general partner of BCLS II Investco. As a result, each of BCLSI II, BCLS Fund II and BCLS II Investco GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS II Investco. Each of BCLSI II, BCLS Fund II and BCLS II Investco GP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. F11 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI") (i) is the general partner of BCLSP, (ii) is the manager of BCLSI II and (iii) governs the investment strategy and decision-making process with respect to investments held by BCIPLS. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 22:48 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | PurchaseCommon Stock | 1,000,000 | $4.03 | $4,030,000.00 |
DisclosureSEC source: 0000950170-25-025011 · ownership.xml · nonDerivative · entry 1 Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner BCLS SB Investco, LP · CIK 0001728056 · 10% owner Bain Capital Life Sciences Partners, LP · CIK 0001703030 · 10% owner Bain Capital Life Sciences Fund II, L.P. · CIK 0001773187 · 10% owner Bain Capital Life Sciences Investors II, LLC · CIK 0001796155 · 10% owner BCLS II Investco, LP · CIK 0001818893 · 10% owner BCLS II Investco (GP), LLC · CIK 0001819101 · 10% owner BCIP Life Sciences Associates, LP · CIK 0001702921 · 10% owner BCLS II Equity Opportunities, LP · CIK 0001814474 · 10% owner BCLS II Equity Opportunities GP, LLC · CIK 0002008174 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 5,034,582 F1 · kind: On February 19, 2025, BCLS II Investco, LP ("BCLS II Investco") purchased 1,000,000 shares of the Issuer's common stock and a pre-funded warrant to purchase 6,444,170 shares of the Issuer's common stock at a purchase price of $4.03 and $4.029, respectively, in an underwritten public offering (the "February 2025 Underwritten Offering"). F4 · ownership.nature: Represents 528,660 shares of the Issuer's common stock held directly by BCLS SB Investco, LP ("BCLS SB"), 267,257 shares of the Issuer's common stock held directly by Bain Capital Life Sciences Fund II, L.P. ("BCLS Fund II"), 3,301,955 shares of the Issuer's common stock held directly by BCLS II Investco, 904,160 shares of the Issuer's common stock held directly by BCLS II Equity Opportunities, LP ("BCLS II Equity") and 32,550 shares of the Issuer's common stock held directly by BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS II Investco, BCLS SB, BCLS Fund II and BCLS II Equity, the "Bain Capital Life Sciences Entities"), after giving effect to the closing of the February 2025 Underwritten Offering. F6 · ownership.nature: Bain Capital Life Sciences Partners, LP ("BCLSP") is the general partner of BCLS SB. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS SB. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. F7 · ownership.nature: Bain Capital Life Sciences Investors II, LLC ("BCLSI II") is the general partner of BCLS Fund II. As a result, BCLSI II may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund II. BCLSI II disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. F8 · ownership.nature: BCLS II Investco (GP), LLC ("BCLS II Investco GP"), whose managing member is BCLS Fund II, is the general partner of BCLS II Investco. As a result, each of BCLSI II, BCLS Fund II and BCLS II Investco GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS II Investco. Each of BCLSI II, BCLS Fund II and BCLS II Investco GP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. F9 · ownership.nature: BCLS II Equity Opportunities GP, LLC ("BCLS II Equity GP"), whose manager is BCLS Fund II, is the general partner of BCLS II Equity. As a result, each of BCLSI II, BCLS Fund II and BCLS II Equity GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS II Equity. Each of BCLSI II, BCLS Fund II and BCLS II Equity GP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. F10 · ownership.nature: Boylston Coinvestors, LLC is the general partner of BCIPLS. F11 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI") (i) is the general partner of BCLSP, (ii) is the manager of BCLSI II and (iii) governs the investment strategy and decision-making process with respect to investments held by BCIPLS. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.